Brief: Algernon Pharmaceuticals Receives Approval For Groundbreaking Phase 1 DMT Human Stroke Study
12/09/2022 12:10
Sept 12 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS RECEIVES APPROVAL FOR
GROUNDBREAKING
PHASE 1 DMT HUMAN STROKE STUDY
* ALGERNON PHARMACEUTICALS INC - PLANS TO BEGIN SCREENING
SHORTLY
AND DOSE FIRST SUBJECT OF STUDY IN Q4, 2022
Source text for Eikon: ID:nGNX1gGDYD
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement